Acute lung injury: A clinical and molecular review

Archives of Pathology and Laboratory Medicine

Volumn 140, Issue 4, 2016, Pages 345-350

  Butt, Yasmeen ^a   Kurdowska, Anna ^b   Allen, Timothy Craig ^c  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF TEXAS HEALTH CENTER   (United States)

^c UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA;

ACUTE LUNG INJURY; COMPLICATION; HUMAN; LUNG; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT;

ACUTE LUNG INJURY; BIOMARKERS; HUMANS; INTERLEUKINS; LUNG; PROGNOSIS; RESPIRATORY DISTRESS SYNDROME, ADULT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84964047913     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2015-0519-RA     Document Type: Review

References (58)

1. Ashbaugh DG, Bigelow DB, Petty TL, Levine BE. Acute respiratory distress in adults. Lancet. 1967;2(7511):319-323.
2. The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301-1308.
3. Gajic O, Dabbagh O, Park PK, et al. Early identification of patients at risk of acute lung injury: evaluation of lung injury prediction score in a multicenter cohort study. Am J Respir Crit Care Med. 2011;183(4):462-470.
4. Ruthman CA, Festic E. Emerging therapies for the prevention of acute respiratory distress syndrome. Ther Adv Respir Dis. 2015;9(4):173-187.
5. Sloggett AT, ed. Memorandum of the Treatment of Injuries in War. London, England: Harrison and Sons; 1915:115-122.
6. Montgomery AB. Early description of ARDS. Chest. 1991;99(1):261-262.
7. Bernard GR, Artigas A, Brigham KL, et al. The American-European Consensus Conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3, pt 1):818-824.
8. ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526-2533.
9. Riviello ED, Kiviri W, Twagirumugabe T, et al. Hospital incidence and outcomes of ARDS using the Kigali modification of the Berlin definition. Am J Respir Crit Care Med. 2016;193(1):52-59.
10. Phua J, Badia JR, Adhikari NK, et al. Has mortality from acute respiratory distress syndrome decreased over time: a systematic review. Am J Respir Crit Care Med. 2009;179(3):220-227.
11. Zompatori M, Ciccarese F, Fasano L. Overview of current lung imaging in acute respiratory distress syndrome. Eur Respir Rev. 2014;23(134):519-530.
12. Ichikado K. High-resolution computed tomography findings of acute respiratory distress syndrome, acute interstitial pneumonia, and acute exacerbation of idiopathic pulmonary fibrosis. Semin Ultrasound CT MR. 2014;35(1):39-46.
13. Katzenstein AL. Acute lung injury patterns: diffuse alveolar damage and bronchiolitis obliterans organizing pneumonia. In: Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. 4th ed. Philadelphia, PA: Saunders Elsevier; 2006:17-50.
14. Katzenstein AL, Myers JL, Mazur MT. Acute interstitial pneumonia: a clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol. 1986; 10(4):256-267.
15. Katzenstein A, Askin F, eds. Katzenstein and Askin's Surgical Pathology of Non-Neoplastic Lung Disease. 3rd ed. Philadelphia, PA: Saunders; 1997.
16. Beasley MB, Franks TJ, Galvin JR, Gochuico B, Travis WD. Acute fibrinous and organizing pneumonia: a histological pattern of lung injury and possible variant of diffuse alveolar damage. Arch Pathol Lab Med. 2002;126(9):1064-1070.
17. Rubenfeld GD, Caldwell E, Peabody E, et al. Incidence and outcomes of acute lung injury. N Engl J Med. 2005;353(16):1685-1693.
18. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell. 2010;140(6):805-820.
19. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A. 1998;95(2):588-593.
20. Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol. 2010;11(5):373-384.
21. Leissinger M, Kulkarni R, Zemans RL, Downey GP, Jeyaseelan S. Investigating the role of nucleotide-binding oligomerization domain-like receptors in bacterial lung infection. Am J Respir Crit Care Med. 2014;189(12):1461-1468.
22. Jiang D, Liang J, Fan J, et al. Regulation of lung injury and repair by Toll-like receptors and hyaluronan. Nat Med. 2005;11(11):1173-1179.
23. Zhang Q, Raoof M, Chen Y, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature. 2010;464(7285):104-107.
24. Ray NB, Durairaj L, Chen BB, et al. Dynamic regulation of cardiolipin by the lipid pump Atp8b1 determines the severity of lung injury in experimental pneumonia. Nat Med. 2010;16(10):1120-1127.
25. Simmons JD, Lee YL, Mulekar S, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects [discussion in Ann Surg. 2013;258(4):596-598]. Ann Surg. 2013; 258(4):591-596.
26. Sun S, Sursal T, Adibnia Y, et al. Mitochondrial DAMPs increase endothelial permeability through neutrophil dependent and independent pathways. PLoS One. 2013;8(3):e59989.
27. Williams AE, Chambers RC. The mercurial nature of neutrophils: still an enigma in ARDS? Am J Physiol Lung Cell Mol Physiol. 2014;306(3):L217-L230.
28. Douda DN, Jackson R, Grasemann H, Palaniyar N. Innate immune collectin surfactant protein D simultaneously binds both neutrophil extracellular traps and carbohydrate ligands and promotes bacterial trapping. J Immunol. 2011;187(4):1856-1865.
29. Bosmann M, Ward PA. Role of C3, C5 and anaphylatoxin receptors in acute lung injury and in sepsis. Adv Exp Med Biol. 2012;946:147-159.
30. Levitt JE, Vinayak AG, Gehlbach BK, et al. Diagnostic utility of B-type natriuretic peptide in critically ill patients with pulmonary edema: a prospective cohort study. Crit Care. 2008;12(1):R3.
31. Rana R, Vlahakis NE, Daniels CE, et al. B-type natriuretic peptide in the assessment of acute lung injury and cardiogenic pulmonary edema. Crit Care Med. 2006;34(7):1941-1946.
32. Luyt CE, Combes A, Reynaud C, et al. Usefulness of procalcitonin for the diagnosis of ventilator-associated pneumonia. Intensive Care Med. 2008;34(8): 1434-1440.
33. Dolinay T, Kim YS, Howrylak J, et al. Inflammasome-regulated cytokines are critical mediators of acute lung injury. Am J Respir Crit Care Med. 2012; 185(11):1225-1234.
34. Schroder K, Tschopp J. The inflammasomes. Cell. 2010;140(6):821-832.
35. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J Exp Med. 2009;206(1):79-87.
36. Andrei C, Margiocco P, Poggi A, Lotti LV, Torrisi MR, Rubartelli A. Phospholipases C and A2 control lysosome-mediated IL-1 beta secretion: implications for inflammatory processes. Proc Natl Acad Sci U S A. 2004; 101(26):9745-9750.
37. Mariathasan S, Weiss DS, Newton K, et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature. 2006;440(7081):228-232.
38. Franchi L, Eigenbrod T, Muñoz-Planillo R, Nuñez G. The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis. Nat Immunol. 2009;10(3):241-247.
39. Lamkanfi M, Dixit VM. Modulation of inflammasome pathways by bacterial and viral pathogens. J Immunol. 2010;187(2):597-602.
40. Hornung V, Bauernfeind F, Halle A, et al. Silica crystals and aluminum salts activate the nalp3 inflammasome through phagosomal destabilization. Nat Immunol. 2008;9(8):847-856.
41. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature. 2006;440(7081):237-241.
42. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. Thioredoxin interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010; 11(2):136-140.
43. Nakahira K, Haspel JA, Rathinam VA, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol. 2011;12(3):212-220.
44. Rathinam VA, Jiang Z, Waggoner SN, et al. The AIM2 inflammasome is essential for host defense against cytosolic bacteria and DNA viruses. Nat Immunol. 2010;11(5):395-402.
45. Krupa A, Kato H, Matthay MA, Kurdowska AK. Proinflammatory activity of anti-IL-8 autoantibody:IL-8 complexes in alveolar edema fluid from patients with acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2004;286(6):L1105-L1113.
46. Fudala R, Krupa A, Matthay MA, Allen TC, Kurdowska AK. Anti-IL-8 autoantibody: IL-8 immune complexes suppress spontaneous apoptosis of neutrophils. Am J Physiol Lung Cell Mol Physiol. 2007;293(2):L364-L374.
47. Kurdowska A, Miller EJ, Noble JM, et al. Anti-IL-8 autoantibodies in alveolar fluid from patients with the adult respiratory distress syndrome. J Immunol. 1996;157(6):2699-2706.
48. Kurdowska A, Noble JM, Steinberg KP, Ruzinski JT, Hudson LD, Martin TR. Anti-interleukin 8 autoantibody: interleukin 8 complexes in the acute respiratory distress syndrome: relationship between the complexes and clinical disease activity. Am J Respir Crit Care Med. 2001;163(2):463-468.
49. Kurdowska A, Noble JM, Grant IS, Robertson CR, Haslett C, Donnelly SC. Anti-interleukin-8 autoantibodies in patients at risk for acute respiratory distress syndrome. Crit Care Med. 2002;30(10):2335-2337.
50. Terpstra ML, Aman J, Van Nieuw Amerongen GP, Groeneveld AB. Plasma biomarkers for acute respiratory distress syndrome: a systematic reviewand metaanalysis. Crit Care Med. 2014;42(3):691-700.
51. Koh H, Tasaka S, Hasegawa N, et al. Vascular endothelial growth factor in epithelial lining fluid of patients with acute respiratory distress syndrome. Respirology. 2008;13(2):281-284.
52. Stern JB, Fierobe L, Paugam C, et al. Keratinocyte growth factor and hepatocyte growth factor in bronchoalveolar lavage fluid in acute respiratory distress syndrome patients. Crit Care Med. 2000;28(7):2326-2333.
53. Meduri GU, Annane D, Chrousos GP, Marik PE, Sinclair SE. Activation and regulation of systemic inflammation in ARDS: rationale for prolonged glucocorticoid therapy. Chest. 2009;136(6):1631-1643.
54. Kress JP. Mortality is the only relevant outcome in ARDS: no. Intensive Care Med. 2015;41(1):144-146.
55. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS: persistent elevation over time predicts poor outcome. Chest. 1995;108(5):1303-1314.
56. Agrawal A, Zhuo H, Brady S, et al. Pathogenetic and predictive value of biomarkers in patients with ALI and lower severity of illness: results from two clinical trials. Am J Physiol Lung Cell Mol Physiol. 2012;303(8):L634-L639.
57. Calfee CS, Ware LB, Glidden DV, et al; National Heart, Blood, and Lung Institute Acute Respiratory Distress Syndrome Network. Use of risk reclassification with multiple biomarkers improves mortality prediction in acute lung injury. Crit Care Med. 2011;39(4):711-717.
58. Ware LB, Koyama T, Billheimer DD, et al. Prognostic and pathogenetic value of combining clinical and biochemical indices in patients with acute lung injury. Chest. 2010;137(2):288-296.